Pablo J. Cagnoni

Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies

Bret Wacker, Tina Nagrani, Jacqueline Weinberg et al. · Clinical Cancer Research · 2007 · 383 citations

Medicine, Oncology, Pharmacology +16

Effects of Smoking on the Pharmacokinetics of Erlotinib

Marta Hamilton, Julie Wolf, Jason Rusk et al. · Clinical Cancer Research · 2006 · 311 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality

Ashwin Kashyap, John R. Wingard, Pablo J. Cagnoni et al. · Biology of Blood and Marrow Transplantation · 2002 · 225 citations · Full text

Pharmacy, Hematology, Pharmacology +17

Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases

John H. Suh, Baldassarre Stea, Abdenour Nabid et al. · Journal of Clinical Oncology · 2005 · 194 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Elizabeth Buck, Alexandra Eyzaguirre, Sharon Barr et al. · Molecular Cancer Therapeutics · 2007 · 189 citations

Life Sciences, Cell Biology, Oncology +17